慕尚(01817.HK)不接受思捷(00330.HK)指控 拟就任何诉讼极力抗辩
慕尚集团控股(01817.HK)公司,公司并不接受思捷环球(00330.HK)法律顾问函件内作出的任何指控,并拟本公司在合营协议项下的权利及思捷可能提出的任何诉讼极力抗辩。
公司失望的是,尽管一直努力成立合营公司,但思捷於并无任何有效及正当理由的情况下向公司发出该函件。公司无意对思捷所作行动的背後理由作猜测,但坚持公司就合营协议与思捷交易时仍符合其一贯商业规范及规程的最高标准。
7月30日,公司收到思捷全资附属万成的中国法律顾问发出函件,声言合营协议终止、公司违反合营协议以及申索5,000万人民币的违约赔偿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.